Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03999853Phase 1Completed

Butyrate Adjuvant Therapy for Type 1 Diabetes

Role: collaborator

NCT06556745Recruiting

Pharmacokinetics of Butyrate Tablet BKR-017

Role: lead

NCT04673656Not ApplicableCompleted

Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

Role: lead

NCT04279444Not ApplicableCompleted

Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients

Role: lead

NCT03382015Not ApplicableCompleted

Effect of BKR-013 on Average Daily Glucose Levels

Role: lead

All 5 trials loaded